HER2- Locally Advanced Metastatic Breast Cancer | Norton Healthcare

Indication: HER2- Locally Advanced Metastatic Breast Cancer

A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Efficacy And Safety Of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib In Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced Or Metastatic Breast Cancer

Sub-indication: Breast Cancer

Study Type: Drug Study

Principal Investigator: Jeffrey Hargis, M.D.
Norton Cancer Institute

Sponsor: Sponsor: F. Hoffmann-LaRoche Ltd.

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.